AAAAAA
Results: 1-25/40
Authors:
McCluskie, MJ
Weeratna, RD
Payette, PJ
Davis, HL
Citation: Mj. Mccluskie et al., The potential of CpG oligodeoxynucleotides as mucosal adjuvants, CR R IMMUN, 21(1-3), 2001, pp. 103-120
Authors:
Payette, PJ
Weeratna, RD
McCluskie, MJ
Davis, HL
Citation: Pj. Payette et al., Immune-mediated destruction of transfected myocytes following DNA vaccination occurs via multiple mechanisms, GENE THER, 8(18), 2001, pp. 1395-1400
Authors:
Chen, Y
Lenert, P
Weeratna, R
McCluskie, M
Wu, T
Davis, HL
Krieg, AM
Citation: Y. Chen et al., Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs, GENE THER, 8(13), 2001, pp. 1024-1032
Authors:
Weeratna, RD
Millan, CLB
McCluskie, MJ
Siegrist, CA
Davis, HL
Citation: Rd. Weeratna et al., Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies, FEMS IM MED, 30(3), 2001, pp. 241-247
Authors:
McCluskie, MJ
Weeratna, RD
Clements, JD
Davis, HL
Citation: Mj. Mccluskie et al., Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants, VACCINE, 19(27), 2001, pp. 3759-3768
Authors:
McCluskie, MJ
Weeratna, RD
Davis, HL
Citation: Mj. Mccluskie et al., The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants, VACCINE, 19(17-19), 2001, pp. 2657-2660
Authors:
Malanchere-Bres, E
Payette, PJ
Mancini, M
Tiollais, P
Davis, HL
Michel, ML
Citation: E. Malanchere-bres et al., CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-Transgenic mice, J VIROLOGY, 75(14), 2001, pp. 6482-6491
Authors:
Ballas, ZK
Krieg, AM
Warren, T
Rasmussen, W
Davis, HL
Waldschmidt, M
Weiner, GJ
Citation: Zk. Ballas et al., Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs, J IMMUNOL, 167(9), 2001, pp. 4878-4886
Authors:
Gallichan, WS
Woolstencroft, RN
Guarasci, T
McCluskie, MJ
Davis, HL
Rosenthal, KL
Citation: Ws. Gallichan et al., Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in thegenital tract, J IMMUNOL, 166(5), 2001, pp. 3451-3457
Authors:
Gramzinski, RA
Doolan, DL
Sedegah, M
Davis, HL
Krieg, AM
Hoffman, SL
Citation: Ra. Gramzinski et al., Interleukin-12-and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice, INFEC IMMUN, 69(3), 2001, pp. 1643-1649
Authors:
Kovarik, J
Bozzotti, P
Tougne, C
Davis, HL
Lambert, PH
Krieg, AM
Siegrist, CA
Citation: J. Kovarik et al., Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens, IMMUNOLOGY, 102(1), 2001, pp. 67-76
Authors:
McCluskie, MJ
Weeratna, RD
Davis, HL
Citation: Mj. Mccluskie et al., Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigendistribution, MOL MED, 6(10), 2000, pp. 867-877
Authors:
McCluskie, MJ
Weeratna, RD
Davis, HL
Citation: Mj. Mccluskie et al., The role of CpG in DNA vaccines, SPR SEM IMM, 22(1-2), 2000, pp. 125-132
Authors:
Weeratna, RD
McCluskie, MJ
Comanita, L
Wu, T
Davis, HL
Citation: Rd. Weeratna et al., Optimization strategies for DNA vaccines, INTERVIROLO, 43(4-6), 2000, pp. 218-226
Authors:
Forns, X
Payette, PJ
Ma, XY
Satterfield, W
Eder, G
Mushahwar, IK
Govindarajan, S
Davis, HL
Emerson, SU
Purcell, RH
Bukh, J
Citation: X. Forns et al., Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus(HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV, HEPATOLOGY, 32(3), 2000, pp. 618-625
Authors:
McCluskie, MJ
Weeratna, RD
Krieg, AM
Davis, HL
Citation: Mj. Mccluskie et al., CpG DNA is an effective oral adjuvant to protein antigens in mice, VACCINE, 19(7-8), 2000, pp. 950-957
Authors:
McCluskie, MJ
Davis, HL
Citation: Mj. Mccluskie et Hl. Davis, Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants, VACCINE, 19(4-5), 2000, pp. 413-422
Authors:
Davis, HL
Suparto, I
Weeratna, R",Jumintarto,"Iskandriati, D
Chamzah, S
Ma'ruf, A
Nente, C
Pawitri, D
Krieg, AM",Heriyanto,"Smits, W
Sajuthi, D
Citation: Hl. Davis et al., CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans, VACCINE, 18(18), 2000, pp. 1920-1924
Authors:
Weeratna, RD
McCluskie, MJ
Xu, Y
Davis, HL
Citation: Rd. Weeratna et al., CpG DNA induces stronger immune responses with less toxicity than other adjuvants, VACCINE, 18(17), 2000, pp. 1755-1762
Authors:
Heppell, J
Davis, HL
Citation: J. Heppell et Hl. Davis, Application of DNA vaccine technology to aquaculture, ADV DRUG DE, 43(1), 2000, pp. 29-43
Authors:
Davis, HL
Citation: Hl. Davis, Use of CpG DNA for enhancing specific immune responses, CURR T MICR, 247, 2000, pp. 171-183
Authors:
Davis, HL
Citation: Hl. Davis, The rise and demise of Howdy-Doody: A backstage story by a real insider, TELEV QUART, 30(3), 2000, pp. 70-79
Authors:
Hartmann, G
Weeratna, RD
Ballas, ZK
Payette, P
Blackwell, S
Suparto, I
Rasmussen, WL
Waldschmidt, M
Sajuthi, D
Purcell, RH
Davis, HL
Krieg, AM
Citation: G. Hartmann et al., Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo, J IMMUNOL, 164(3), 2000, pp. 1617-1624
Authors:
Davis, HL
Citation: Hl. Davis, Intramuscular and intradermal injection of DNA vaccines in mice and primates, METH MOL M, 29, 2000, pp. 71-77
Authors:
Millan, CLB
Davis, HL
Citation: Clb. Millan et Hl. Davis, DNA-based immunization of neonatal mice, METH MOL M, 29, 2000, pp. 95-98